Wegovy
Excellus BlueCross BlueShield says GLP-1 drugs for diabetes will remain on formulary, countering reports of a blanket halt. Effective January 1, 2026, three GLP-1s for weight loss—Wegovy, Zepbound, and Saxenda—will be removed from covered lists for certain plans, though members can seek exceptions if prescribers verify criteria. The insurer cites Pharmacy & Therapeutics Committee review […]
The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment. The new rule, which was proposed by the administration Tuesday, would dramatically expand access to anti-obesity medications such as Ozempic and Wegovy, from Novo Nordisk, and Mounjaro and Zepbound, from Eli Lilly. Medicare has […]
GLP-1 drugs, such as Wegovy, Ozempic, and Zepbound, originally developed for diabetes and weight loss, are showing promise in preventing certain cancers. These medications work by regulating hormones, slowing digestion, and reducing hunger, which helps manage obesity—a key risk factor for cancers like breast, colon, liver, and ovarian. Recent studies suggest that GLP-1 drugs can […]
A shortage of popular weight loss drugs like Wegovy and Ozempic have prompted a skyrocketing demand. Which has also lead to scammers on social media offering to ship weight loss drugs for lower prices — and without a prescription. A joint investigation conducted from February through April by the nonprofits Digital Citizens Alliance and Coalition […]
-
Pages
WDKX Holiday Stream